avail
rapid
reliabl
viral
diagnost
test
particularli
nucleic
acid
amplif
test
naat
facilit
decisionmak
prevent
treatment
viral
infect
practic
effect
infect
control
measur
specif
antivir
therapi
avail
mani
clinic
relev
virus
correct
viral
diagnosi
import
also
limit
diagnost
test
unnecessari
antibiot
therapi
two
major
approach
diagnosi
viral
infect
virolog
detect
viru
serolog
detect
antibodi
antigen
virolog
approach
includ
isol
infecti
viru
cell
cultur
detect
viral
antigen
immunolog
method
fluoresc
antibodi
fa
test
enzym
immunoassay
eia
identif
viral
particl
electron
microscopi
em
detect
viral
nucleic
acid
direct
hybrid
naat
polymeras
chain
reaction
pcr
may
qualit
quantit
refer
avail
onlin
wwwexpertconsultcom
cytolog
examin
tissu
cell
identifi
viral
effect
prompt
investig
occasion
cytolog
chang
suffici
specif
suggest
particular
agent
eg
cytomegaloviru
cmv
serolog
approach
diagnosi
viral
infect
includ
demonstr
immunoglobulin
ig
g
antibodi
indic
recent
current
past
infect
well
immun
follow
recoveri
vaccin
signific
rise
virusspecif
igg
antibodi
suggest
acut
recent
infect
virusspecif
antigen
eg
hepat
b
surfac
antigen
hbsag
virusspecif
igm
antibodi
late
acuteor
earli
recoveryphas
sera
immun
respons
matur
follow
viral
infect
lowavid
igg
antibodi
replac
highavid
antibodi
eia
capabl
measur
avid
igg
antibodi
specif
virus
use
distinguish
primari
secondari
antibodi
respons
vaccin
natur
infect
clinic
set
laboratori
test
detect
viru
infect
divid
three
specif
categori
use
make
specif
viral
diagnosi
measur
viral
activ
patient
known
infect
eg
viral
load
test
hiv
screen
infect
eg
pretranspl
blood
donat
detect
virus
import
obtain
specimen
soon
onset
clinic
symptom
prefer
within
first
day
viral
shed
maxim
optim
specimen
vari
depend
site
diseas
gener
tissu
aspir
bodi
fluid
superior
swab
howev
mani
circumst
swab
may
specimen
avail
bodi
site
lesion
sampl
easili
swab
includ
pharynx
nasopharynx
conjunctiva
urethra
cervix
vagina
vesicl
ulcer
skin
mucou
membran
mani
type
swab
avail
specimen
collect
includ
plastic
wooden
flexibl
wire
shaft
tip
made
cotton
dacron
calcium
algin
polyurethan
howev
certain
swab
may
suitabl
detect
virus
swab
wooden
shaft
contain
toxic
product
inactiv
herp
simplex
viru
hsv
cottontip
swab
contain
fatti
acid
interfer
surviv
chlamydia
speci
suitabl
collect
specimen
vagina
cervix
urethra
detect
mycoplasma
calcium
alginatetip
swab
toxic
lipidenvelop
virus
herpesvirus
cell
cultur
use
collect
specimen
chlamydia
although
swab
place
viral
transport
media
vtm
use
naat
mani
commerci
assay
detect
virus
chlamydia
antigen
detect
molecular
techniqu
provid
swab
transport
media
use
swab
tissu
detect
virus
place
vtm
prevent
dri
maintain
viral
viabil
transport
prevent
overgrowth
contamin
organ
number
commerci
prepar
vtm
avail
swab
collect
bacteri
isol
place
bacteri
transport
medium
unaccept
detect
virus
convers
vtm
contain
antimicrobi
agent
inhibit
bacteria
fungi
specimen
blood
bone
marrow
cerebrospin
fluid
csf
urin
bodi
fluid
place
clean
steril
contain
without
vtm
detect
respiratori
virus
nasopharyng
np
aspir
wash
sputum
bronchoalveolar
lavag
bal
specimen
provid
better
yield
detect
virus
np
nasal
throat
swab
multipl
sampl
may
requir
maxim
yield
freshli
pass
stool
superior
rectal
swab
detect
gastrointestin
virus
specif
virus
found
differ
blood
cell
plasmaserum
eg
hiv
lymphocyt
macrophag
cmv
neutrophil
lesser
extent
mononuclear
cell
enterovirus
plasma
white
blood
cell
wbc
blood
collect
vacutain
tube
contain
anticoagul
ethylenediaminetetraacet
acid
edta
recoveri
rate
higher
edta
heparin
heparin
inactiv
herpesvirus
inhibit
naat
may
less
concern
realtim
pcr
may
relat
type
heparin
sodium
versu
lithium
use
tissu
specimen
labil
particular
virus
eg
respiratori
syncyti
viru
rsv
varicellazost
viru
vzv
concern
commerci
avail
vtm
contain
albumin
serum
stabil
use
virus
stabl
day
refriger
wet
ice
temperatur
freez
ordinari
freezer
temperatur
destroy
reduc
infect
virus
alter
abil
detect
viral
antigen
use
commerci
avail
kit
beyond
day
specimen
store
ultralowtemperatur
freezer
transport
dri
ice
naat
eg
detect
hepat
c
viru
hcv
rna
serumplasma
recommend
serumplasma
separ
within
hour
collect
process
within
hour
kept
frozen
test
serolog
detect
viral
antibodi
antigen
blood
transport
room
temperatur
delay
anticip
specimen
kept
refriger
serum
plasma
separ
soon
possibl
specimen
collect
extend
period
elaps
test
serumplasma
sampl
frozen
lower
repeat
freezethaw
cycl
avoid
virus
igm
assay
avail
eg
hepat
viru
hav
acutephas
specimen
suffici
diagnosi
otherwis
acutephas
specimen
collect
within
day
ill
onset
follow
convalescentphas
specimen
collect
week
later
obtain
monolay
cell
cultur
techniqu
use
laboratori
viru
isol
howev
mani
clinic
relev
virus
parvoviru
human
papillomaviru
hpv
hepat
virus
epsteinbarr
viru
ebv
rotavirus
norovirus
other
cultivat
routin
diagnost
laboratori
laboratori
diagnosi
base
method
although
possibl
cultiv
hiv
use
suspens
cultur
lymphocyt
special
contain
facil
requir
altern
method
use
routin
diagnosi
major
virus
detect
isol
monolay
cell
cultur
includ
cmv
vzv
rsv
influenza
b
virus
parainfluenza
virus
respiratori
adenovirus
number
enterovirus
coxsackieviru
echoviru
polioviru
measl
viru
cultivat
virus
replic
singl
cell
line
sever
differ
cell
line
use
primari
isol
exampl
isol
diploid
cell
line
eg
human
foreskin
lung
fibroblast
herpesvirus
primari
cell
line
primari
rhesu
monkey
kidney
cell
respiratori
virus
enterovirus
heteroploid
continu
human
epitheli
cell
line
cell
rsv
type
cell
line
use
diagnost
laboratori
determin
specimen
type
season
epidemiolog
data
clinic
inform
provid
mani
virus
caus
morpholog
chang
ie
cytopath
effect
cpe
cell
monolay
virus
caus
cpe
within
day
eg
hsv
other
within
week
eg
enterovirus
other
sever
week
eg
cmv
virus
caus
typic
cpe
detect
base
adsorpt
red
cell
surfac
virusinfect
cell
cultur
eg
influenza
parainfluenza
virus
use
interfer
assay
eg
rubella
viru
presumpt
identif
particular
viru
viru
group
cell
cultur
base
cell
type
characterist
time
onset
appear
cpe
facilit
laboratori
personnel
inform
sourc
specimen
suspect
clinic
diagnosi
confirm
viru
isol
requir
immunolog
method
fluoresceinor
peroxidaseconjug
virusspecif
monoclon
polyclon
antibodi
antibodi
hsv
cmv
vzv
rsv
influenza
b
viru
parainfluenza
viru
antigen
neutrophil
use
commonli
diagnosi
manag
immunocompromis
patient
new
reactiv
cmv
infect
varieti
specimen
type
collect
process
properli
suitabl
em
experienc
microscopist
identifi
viral
pathogen
morpholog
within
minut
arriv
specimen
laboratori
unlik
antigen
detect
naat
limit
abil
detect
virus
differ
antigen
determin
nucleic
acid
sequenc
respect
high
specif
reagent
use
em
detect
base
morpholog
characterist
use
broadli
detect
member
differ
viru
famili
well
potenti
novel
agent
em
continu
use
detect
gastrointestin
pathogen
rotaviru
enter
adenovirus
noroviru
other
well
nonenter
virus
disadvantag
em
includ
larg
number
viru
particl
approxim
per
ml
specimen
requir
detect
limit
throughput
expens
lack
avail
expertis
mani
center
nucleic
acid
detect
molecular
hybrid
techniqu
use
probe
direct
uniqu
conserv
portion
viral
genom
highli
specif
bind
complementari
dna
rna
sequenc
probe
particularli
use
detect
type
virus
reliabl
cultur
method
avail
molecular
probe
avail
commerci
kit
detect
hpv
hiv
hsv
cmv
hepat
b
viru
hbv
hcv
virus
concentr
viral
genom
direct
patient
specimen
may
low
permit
detect
adequ
sensit
eg
commerci
avail
probe
hsv
cmv
detect
specimen
posit
isol
increas
sensit
naat
revolution
test
clinic
virolog
laboratori
three
approach
taken
target
amplif
pcr
strand
displac
amplif
sda
nucleic
acid
sequencebas
amplif
nasba
transcriptionmedi
amplif
tma
system
probe
amplif
includ
qbeta
replicas
ligas
chain
reaction
lcr
signal
amplif
branchedchain
dna
bdna
assay
hybrid
captur
assay
sever
commerci
inhous
homebrew
adenoviru
measl
viru
enteroviru
antigen
avail
readili
centrifug
specimen
also
refer
shell
vial
cultur
spinamplifi
cultur
onto
cell
monolay
coverslip
place
bottom
small
vial
well
follow
incub
stain
viral
antigen
use
monoclon
antibodi
day
substanti
reduc
time
requir
detect
confirm
presenc
mani
virus
slowli
grow
virus
cmv
use
monoclon
antibodi
nonstructur
protein
produc
earli
replic
cycl
ie
immedi
earli
antigen
earli
antigen
allow
detect
viru
day
week
cpe
observ
tradit
cell
cultur
techniqu
speed
shell
vial
method
replac
convent
cultur
mani
laboratori
tabl
use
routin
detect
cmv
hsv
vzv
respiratori
virus
enterovirus
two
techniqu
isol
virus
develop
compar
sensit
standard
cultur
shell
vial
method
use
genet
engin
cell
line
elvi
enzymelink
virusinduc
system
introduc
first
isol
hsv
babi
hamster
kidney
cell
line
transform
use
hsvinduc
promot
gene
e
coli
gene
addit
substrat
enzym
result
format
color
reaction
hsvinfect
cell
techniqu
adapt
perform
rapid
hsv
antivir
suscept
test
mix
multipl
cell
type
singl
shell
vial
cultur
provid
rapid
detect
respiratori
virus
rmix
hsv
cmv
vzv
h
v
mix
enterovirus
emix
antigen
detect
test
perform
directli
varieti
specimen
type
highli
specif
rapid
viabl
viru
requir
detect
viru
antigen
cellassoci
collect
adequ
number
infect
cell
import
number
commerci
kit
eia
latex
agglutin
fa
avail
detect
rotaviru
enter
adenoviru
stool
specimen
rsv
influenza
b
virus
parainfluenza
virus
adenovirus
respiratori
tract
specimen
hbsag
hiv
antigen
serum
hsv
vzv
vesicl
ulcer
swab
specimen
cmv
bal
blood
specimen
fa
techniqu
use
detect
rabi
viru
brain
tissu
mump
viru
throat
urin
sediment
measl
viru
conjunctiv
cell
detect
cmv
refer
avail
onlin
wwwexpertconsultcom
convalesc
sera
test
parallel
confirm
diagnosi
fall
titer
also
presumpt
evid
recent
infect
wherea
unchang
low
titer
indic
past
infect
immun
presenc
antibodi
high
titer
singl
serum
specimen
convalesc
usual
permit
definit
diagnosi
acut
seroconvers
also
use
diagnos
acut
recent
infect
eia
kit
lesser
extent
latex
agglutin
fa
kit
replac
antibodi
test
mani
laboratori
eia
elisa
result
usual
measur
optic
densiti
od
unit
result
report
intern
unit
iu
index
valu
interpret
od
unit
vari
eiaelisa
kit
use
viru
antibodi
detect
one
must
refer
specif
kit
manufactur
criteria
defin
signific
differ
antibodi
level
acut
convalesc
sera
presenc
virusspecif
igm
antibodi
serum
obtain
week
onset
ill
permit
diagnosi
acut
recent
infect
mani
virus
typic
igm
antibodi
disappear
serum
within
month
acut
ill
persist
extend
time
individu
virus
falseposit
igm
result
occur
crossreact
eg
among
herpesvirus
due
polyclon
stimul
secondari
ebv
infect
presenc
rheumatoid
factor
igm
antibodi
bind
fc
portion
igg
inher
test
difficulti
misinterpret
igm
antibodi
indic
acuterec
infect
occur
result
persist
igm
antibodi
sever
month
acut
ill
eg
ebv
west
nile
viru
reactiv
latent
chronic
virus
eg
hsv
hbv
falseneg
igm
test
result
absent
low
delay
igm
respons
especi
immunolog
immatur
host
eg
infanc
congenit
cmv
hiv
infect
immunosuppress
patient
eg
patient
aid
presenc
hightit
igg
antibodi
preclud
bind
igm
mani
commerci
avail
kit
contain
reagent
adsorb
igg
test
serum
use
background
substract
step
thu
reduc
possibl
interfer
use
igg
antibodi
test
determin
suscept
immun
particular
viru
sensit
method
import
gener
complement
fixat
cf
antibodi
titer
quantit
lower
hemagglutin
inhibit
hai
titer
disappear
sever
year
therefor
cf
use
determin
suscept
immun
major
advantag
serolog
diagnosi
acut
viral
infect
includ
noncrit
specimen
handl
wide
avail
disadvantag
includ
requir
acut
convalesc
sera
igg
antibodi
test
falseposit
falseneg
igm
antibodi
result
delay
week
assay
develop
quantif
viral
genom
plasma
serum
use
determin
prognosi
select
patient
antivir
therapi
monitor
respons
treatment
varieti
patient
popul
multiplex
assay
capabl
detect
number
virus
singl
amplif
reaction
develop
eg
herpesvirus
enter
bloodborn
respiratori
virus
develop
autom
realtim
pcr
use
fluoresc
techniqu
continu
detect
amplifi
product
shorten
detect
time
significantli
rel
convent
pcr
assay
assay
use
close
system
ie
amplif
detect
occur
singl
tube
need
open
reaction
complet
also
less
prone
contamin
naat
appli
genotyp
virus
eg
hiv
hbv
hcv
well
detect
mutat
confer
resist
antivir
agent
choos
optim
test
depend
viru
sought
clinic
set
specimen
type
avail
kit
reagent
equip
experi
laboratori
personnel
cost
antigen
detect
method
offer
follow
advantag
noncrit
specimen
collect
transport
condit
abil
detect
virus
cultiv
easili
need
cell
cultur
equip
highli
train
personnel
superior
sensit
compar
cultur
certain
virus
rapid
turnaround
time
usual
within
hour
disadvantag
includ
lack
avail
test
kit
mani
clinic
import
virus
inferior
sensit
compar
isol
mani
cultivat
virus
inferior
specif
due
nonspecificcrossreact
particularli
use
polyclon
antibodi
cultur
prefer
result
avail
quickli
shell
vial
centrifug
stain
method
eg
hsv
cmv
vzv
advantag
isol
includ
abil
recov
broad
rang
virus
avail
infecti
agent
character
specif
superior
sensit
compar
antigen
detect
virus
disadvantag
includ
requir
special
equip
suppli
train
personnel
longer
turnaround
time
labil
certain
virus
suboptim
collect
transport
condit
inabl
cultur
mani
clinic
relev
virus
use
naat
rapidli
replac
older
viral
diagnost
method
due
rapid
turnaround
time
superior
sensit
abil
quantifi
viru
densiti
number
rel
simpl
homebrew
commerci
avail
naat
includ
analytespecif
research
use
avail
wide
varieti
virus
serolog
method
serolog
method
use
diagnos
current
recent
acut
infect
determin
specif
suscept
immun
epidemiolog
surveil
purpos
interpret
serolog
result
virusspecif
eg
presenc
hiv
antibodi
indic
current
infect
wherea
presenc
igg
antirubella
indic
immun
result
immun
recoveri
natur
infect
serolog
diagnosi
acut
infect
use
incub
period
prolong
eg
week
antibodi
present
serum
concomitantli
sign
ill
eg
ebv
cmv
mononucleosi
figur
show
typic
antibodi
respons
acut
moderateincub
sever
day
week
viral
ill
measl
onset
rash
manifest
antibodi
undetect
present
low
titer
within
day
appreci
titer
antibodi
present
shortincub
viru
infect
eg
respiratori
virus
rise
antibodi
usual
occur
late
recoveri
phase
convalesc
valu
acut
diagnosi
use
older
serolog
method
hemagglutin
inhibit
hai
complement
fixat
cf
detect
igg
antibodi
rise
titer
base
serial
dilut
endpoint
acut
diagnosi
confirm
shortincub
infect
mani
confound
factor
eg
passiv
transfer
antibodi
mother
infant
receipt
immunoglobulin
immunocompromis
serolog
result
alway
interpret
within
context
clinic
situat
whenev
possibl
serolog
diagnosi
confirm
use
viral
isol
direct
detect
viru
antigen
nucleic
acid
depend
serolog
assay
either
serum
andor
plasma
use
use
specimen
type
well
valid
virus
except
includ
use
saliva
detect
hiv
antibodi
csf
patient
viral
central
nervou
system
cn
diseas
optim
test
specif
virus
tabl
list
medic
import
virus
major
attribut
diseas
optim
diagnost
specimen
avail
test
averag
time
posit
test
result
mani
test
time
obtain
result
may
function
test
eg
cultur
logist
laboratori
test
schedul
need
refer
sampl
refer
lab
prefer
test
provid
rapid
result
accept
sensit
specif
serolog
test
remain
mainstay
diagnosi
certain
viru
infect
hepat
virus
prefer
diagnost
test
test
vari
depend
patient
popul
test
eg
immunocompromis
host
result
summar
herein
individu
virus
assess
sensit
specif
differ
test
may
base
varieti
paramet
simpli
comparison
cultur
alon
diagnosi
suspect
mucocutan
lesion
due
hsv
aspir
swab
dacron
rayon
cotton
aluminum
shaft
calcium
algin
swab
wood
shaft
vesicular
fluid
ulcer
base
place
vtm
recommend
potenti
use
sampl
includ
blood
edta
pcr
viremia
suspect
eg
neonat
csf
steril
contain
hsv
mening
enceph
suspect
conjunctiv
swab
corneal
scrape
vtm
suspect
case
herp
kerat
tissu
biopsi
vtm
frozen
eg
dissemin
hsv
neonat
immunocompromis
patient
infant
duoden
aspir
may
also
collect
yield
cultur
vari
depend
tissu
cultur
cell
type
use
laboratori
stage
clinic
infect
greater
vesicular
stage
crust
stage
type
specimen
includ
transport
time
condit
cpe
sensit
cell
line
detect
posit
hour
hour
hour
shell
vial
method
permit
detect
hsv
sensit
specif
hour
elvi
sensit
similar
standard
shell
vial
cultur
use
typespecif
monoclon
antibodi
distinguish
cultur
direct
antigen
detect
test
hsv
variabl
sensit
specif
none
suffici
sensit
reliabl
detect
asymptomat
shed
assay
use
monoclon
antibodi
distinguish
cn
hsv
infect
yield
csf
cultur
compar
biopsyproven
case
hsv
pcr
perform
csf
sensit
specif
diagnost
test
choic
hsv
enceph
mening
pcr
posit
least
first
day
ill
even
patient
receiv
acyclovir
therapi
convers
neg
result
obtain
csf
sampl
infant
children
hsv
pcr
alon
exclud
hsv
enceph
hsv
pcr
also
use
clinic
specimen
type
distinguish
role
quantit
hsv
pcr
remain
unclear
conflict
result
amount
hsv
csf
prognost
valu
howev
success
antivir
therapi
associ
declin
hsv
viral
load
csf
hsvspecif
igg
igm
antibodi
detect
serum
day
onset
primari
infect
igg
antibodi
indic
past
current
infect
necessarili
activ
diseas
presenc
hsv
igg
antibodi
organ
transplant
recipi
use
risk
factor
recurr
prompt
prophylact
use
acyclovir
fluctuat
hsv
igg
antibodi
titer
serolog
test
use
diagnos
recurr
hsv
infect
igm
antibodi
reliabl
indic
primari
infect
reactiv
caus
rise
igm
level
older
hsv
antibodi
test
use
crude
antigen
mixtur
could
reliabl
distinguish
igg
antibodi
howev
commerci
avail
eia
western
blot
wb
immunoblot
test
base
glycoprotein
g
antigen
reliabl
distinguish
typespecif
hsv
antibodi
use
typespecif
assay
provid
import
inform
insensit
clinic
histori
epidemiolog
genit
hsv
infect
recommend
propos
appropri
use
serolog
test
igm
test
commerci
avail
distinguish
infect
guidelin
standard
vitro
suscept
test
hsv
publish
resist
acyclovir
drug
emerg
clinic
problem
immunocompromis
patient
receiv
prolong
cours
continu
intermitt
suppress
therapi
pcr
togeth
sequenc
analysi
dna
polymeras
thymidin
kinas
gene
use
detect
mutat
confer
drug
resist
significantli
reduc
time
result
howev
approach
limit
fact
one
interpret
presenc
mutat
associ
hsv
antivir
resist
signific
new
novel
mutat
requir
confirm
cmv
detect
varieti
clinic
specimen
isol
antigen
detect
dna
probe
naat
often
difficult
distinguish
asymptomat
shed
urin
cervic
secret
semen
saliva
respiratori
tract
secret
activ
cmv
diseas
isol
cmv
tissu
good
evid
activ
infect
prefer
specimen
test
detect
diagnosi
cmv
depend
clinic
syndrom
immun
function
patient
see
chapter
cytomegaloviru
shell
vial
method
significantli
shorten
detect
time
cmv
compar
convent
cultur
enhanc
detect
cmv
variou
clinic
specimen
multipl
shell
vial
inocul
urin
tissu
bal
blood
specimen
stain
hour
hour
blood
specimen
observ
cpe
day
isol
cmv
urin
obtain
first
week
life
diagnost
congenit
infect
situat
imposs
distinguish
cmv
viruria
relat
primari
infect
reactiv
reinfect
diseas
asymptomat
shed
interpret
presenc
cmv
respiratori
tract
specimen
also
confound
asymptomat
respiratori
tract
shed
immunosuppress
patient
suspect
cmv
test
bal
specimen
may
use
compar
cultur
lung
biopsi
specimen
obtain
patient
cmv
pneumonia
sensit
isol
bal
fluid
specif
demonstr
cmv
antigen
cell
bal
specimen
direct
fluoresc
antibodi
dfa
stain
may
specif
cmv
infect
sensit
reduc
histolog
examin
cell
obtain
bal
presenc
characterist
cmv
intranuclear
inclus
owl
eye
appear
suggest
diagnosi
cmv
pneumonia
detect
cmv
peripher
wbc
cultur
techniqu
may
use
diagnosi
activ
cmv
diseas
predictor
futur
cmv
pneumonia
transplant
recipi
immunocompromis
patient
howev
lack
sensit
cultur
cmv
wbc
led
develop
cmv
antigenemia
assay
immunocytochem
assay
detect
lowermatrix
phosphoprotein
igm
result
occur
patient
acut
ebv
infect
well
patient
high
level
rheumatoid
factor
presenc
cmvspecif
igg
immunolog
immatur
host
immunosuppress
patient
cmv
igm
respons
acut
infect
delay
absent
igm
antibodi
cross
placenta
detect
newborn
diagnost
congenit
infect
howev
product
igm
antibodi
newborn
may
delay
absent
case
thu
neg
result
exclud
congenit
infect
major
use
cmv
igg
serolog
determin
suscept
infect
healthcar
childcar
worker
identifi
cmv
statu
blood
organtissu
donor
recipi
pregnant
women
cmvspecif
igg
avid
assay
may
valu
presenc
lowavid
igg
anticmv
may
better
predictor
recent
infect
igm
alon
thu
increas
likelihood
cmv
transmiss
fetu
howev
substanti
variabl
perform
differ
cmv
avid
assay
preclud
clear
guidanc
use
interpret
addit
test
pcr
viru
isol
amniot
fluid
may
requir
confirm
infect
fetu
standard
vitro
cmv
antivir
suscept
test
establish
despit
util
immunocompromis
cmv
directli
neutrophil
varieti
naat
use
wbc
plasma
serum
whole
blood
assay
wide
use
immunocompromis
patient
lesser
extent
infant
congenit
cmv
infect
assay
quantit
semiquantit
sever
studi
support
relationship
level
cmv
blood
likelihood
activ
emerg
cmv
diseas
assay
use
preemptiv
treatment
strategi
well
monitor
respons
anticmv
therapi
howev
variabl
among
commerci
well
inhous
quantit
cmv
assay
exact
level
cmv
dna
antigenemia
use
initi
preemptiv
therapi
well
establish
potenti
problem
assay
includ
inhibit
pcr
heparin
use
anticoagul
falseneg
find
cmv
antigenemia
assay
process
blood
sampl
delay
beyond
hour
cost
need
technic
expertis
labor
intens
eg
cmv
antigenemia
neither
assay
shown
clearli
superior
diagnosi
cmv
mononucleosi
otherwis
healthi
peopl
test
cmvspecif
igm
prefer
test
howev
igm
antibodi
detect
primari
reactiv
cmv
infect
persist
month
falseposit
cmv
vigor
swab
retriev
cellular
materi
base
vesicular
lesion
optim
yield
vesicular
fluid
although
good
cultur
inadequ
fa
test
pcr
detect
vzv
dna
compar
cultur
fa
advantag
increas
sensit
scrape
older
lesion
abil
distinguish
vaccineversu
wildtyp
vzv
pcr
analysi
csf
confirm
etiolog
cn
syndrom
occur
complic
varicella
zoster
without
cutan
lesion
detect
vzv
dna
csf
pcr
along
detect
vzv
antibodi
csf
recommend
confirm
vzv
cn
infect
multiplex
pcr
assay
capabl
detect
vzv
well
herpesvirus
evalu
may
simplifi
diagnosi
patient
overlap
clinic
syndrom
eg
vesicular
rash
igg
antivzv
use
primarili
assess
suscept
infect
determin
need
vaccin
risk
diseas
expos
individu
determin
durat
protect
postvaccin
acut
vzv
infect
vzv
antibodi
appear
within
day
onset
rash
peak
week
later
rise
igg
antibodi
serum
collect
day
apart
detect
vzvspecif
igm
antibodi
singl
sampl
support
diagnosi
acut
infect
howev
serolog
diagnosi
confound
heterotyp
hsv
antibodi
increas
occur
onethird
patient
primari
hsv
infect
experienc
previou
vzv
infect
fluoresc
antibodi
membran
antigen
fama
consid
gold
standard
detect
vzv
antibodi
detect
neutral
antibodi
vzv
healthi
individu
fama
latex
agglutin
correl
protect
person
occasion
vzv
infect
report
occur
patient
low
level
vzv
antibodi
detect
assay
eia
assay
may
lower
sensit
compar
fama
latex
agglutin
assay
particularli
detect
antibodi
postvaccin
newer
glycoprotein
gp
eia
appear
improv
sensit
older
one
human
herpesviru
type
primari
infect
human
herpesviru
occur
children
age
year
routin
lab
test
usual
perform
detect
antibodi
primari
infect
gener
appear
day
follow
onset
fever
follow
serolog
criteria
consid
diagnost
primari
infect
antibodi
seroconvers
acuteand
convalescentphas
serumplasma
specimen
collect
week
apart
detect
lowavid
igg
antibodi
posit
serum
igm
absenc
igg
antibodi
rise
igg
antibodi
ifa
anticomplementari
immunofluoresc
assay
current
commerci
assay
igg
distinguish
variant
b
crossreact
cmv
antibodi
avid
test
use
differenti
primari
infect
igm
alon
reliabl
indic
acut
recent
infect
igm
also
found
reactiv
reinfect
approxim
adult
detect
igm
time
igm
may
detect
cultureposit
children
acut
primari
infect
viru
recov
cultur
peripher
blood
mononuclear
cell
pbmc
infant
recoveri
wherea
dna
detect
pcr
acut
ill
recoveri
monoclon
antibodi
avail
direct
detect
antigen
patient
resist
correl
clinic
failur
phenotyp
assay
limit
lengthi
turnaround
time
expertis
requir
perform
genotyp
assay
detect
mutat
cmv
phosphotransferas
gene
ul
dna
polymeras
gene
confer
antivir
resist
avail
wide
patient
suspect
ebv
mononucleosi
im
heterophil
antibodi
remain
serolog
test
choic
igm
antibodi
detect
easili
rapidli
use
simpl
spot
agglutin
assay
often
refer
monospot
immunochromatograph
assay
heterophil
antibodi
develop
approxim
adolesc
adult
ebv
im
within
week
onset
ill
respons
delay
individu
repeat
test
may
requir
heterophil
test
neg
ebv
infect
children
year
age
heterophil
antibodi
usual
disappear
within
month
persist
year
acut
ill
patient
persist
interpret
recurr
chronic
im
case
heterophileneg
im
schoolag
children
due
cmv
ebv
proven
ebvspecif
serolog
ebv
serolog
indic
diagnosi
ebv
infect
strongli
suspect
heterophil
test
neg
immunofluoresc
antibodi
ifa
test
consid
gold
standard
although
eia
immunoblot
assay
use
ifa
test
uniform
perform
characterist
wherea
eia
vari
wide
varieti
antigen
prepar
use
differ
kit
use
diagnost
test
igm
antiebv
viral
capsid
antigen
vca
appear
within
week
onset
symptom
disappear
within
month
sensit
specif
falseposit
result
occur
due
presenc
rheumatoid
factor
herpesviru
infect
antinuclear
factor
eia
test
system
falseneg
result
occur
sampl
collect
late
cours
ill
igg
antivc
elev
symptom
ill
persist
life
thu
less
use
diagnosi
acut
infect
remain
reliabl
marker
ebv
seroposit
igg
antiearli
antigen
ea
rise
earli
wherea
igg
antiebna
epsteinbarr
nuclear
antigen
appear
late
gener
week
persist
life
sever
month
recov
im
individu
expect
igg
antibodi
vca
ebna
low
absent
vca
igm
antibodi
well
low
absent
antibodi
ea
see
figur
direct
test
ebv
cultiv
cord
blood
leukocyt
direct
detect
immunofluoresc
stain
detect
dna
perform
laboratori
ebv
isol
oropharyng
wash
circul
lymphocyt
patient
im
pcr
detect
ebv
dna
csf
patient
hiv
infect
strongli
associ
primari
cn
lymphoma
follow
organ
marrow
transplant
use
quantit
ebv
pcr
use
blood
specimen
may
help
predict
develop
posttranspl
lymphoprolif
diseas
rel
merit
test
whole
blood
leukocyt
plasma
serum
unclear
elev
level
ebv
dna
peripher
blood
may
indic
decreas
immunosuppress
therapi
consid
therapi
monoclon
antibodi
ebvspecif
cytotox
lymphocyt
rare
ebv
infect
associ
acut
fulmin
diseas
eg
xlink
lymphoprolif
syndrom
virusassoci
hemophagocyt
syndrom
persist
hightit
ebv
antibodi
except
ebna
characterist
may
absent
diagnosi
depend
detect
viru
genom
diagnosi
chickenpox
herp
zoster
shingl
usual
made
clinic
select
circumst
isol
viru
clinic
sampl
detect
isol
influenza
virus
collect
within
day
symptom
onset
viru
shed
maxim
transport
laboratori
prompt
possibl
specimen
store
process
delay
beyond
day
standard
tube
cultur
isol
influenza
virus
requir
day
shell
vial
shorten
time
detect
hour
may
sensit
standard
cultur
serotyp
influenza
b
virus
isol
cultur
achiev
inhibit
hemagglutin
use
serotypespecif
antiserum
sever
rapid
antigen
detect
kit
includ
pointofcar
test
avail
detect
influenza
influenza
b
togeth
without
distinguish
influenza
b
evalu
rapid
test
detect
season
influenza
viru
well
pandem
viru
indic
rel
poor
sensit
high
specif
test
evalu
fulli
detect
avian
influenza
goodqual
respiratori
specimen
wellpreserv
epitheli
cell
use
dfa
stain
use
monoclon
antibodi
sensit
specif
np
aspir
superior
np
swab
throat
swab
detect
influenza
healthi
volunt
number
differ
pcr
assay
includ
multiplex
respiratori
viru
assay
evalu
sever
studi
show
substanti
increas
sensit
compar
method
includ
cultur
multiplex
assay
capabl
detect
influenza
includ
pandem
b
antivir
resist
mutat
particularli
substitut
confer
resist
oseltamivir
multipl
respiratori
virus
avail
respiratori
virus
numer
virus
includ
human
parainfluenza
virus
type
adenovirus
subtyp
e
rhinovirus
human
coronavirus
sever
acut
respiratori
syndrom
sar
coronaviru
human
metapneumoviru
hmpv
infect
respiratori
tract
caus
clinic
sign
symptom
indistinguish
influenza
rsv
laboratori
diagnosi
may
import
epidemiolog
purpos
implement
appropri
infect
control
measur
reduc
empir
use
antibiot
cultur
parainfluenza
virus
adenovirus
requir
approxim
day
posit
result
laboratori
routin
attempt
isol
rhinovirus
routin
cultur
method
avail
isol
coronavirus
hmpv
dfa
stain
avail
parainfluenza
virus
adenovirus
interpret
causal
role
adenoviru
confound
latenc
reactiv
antigen
detect
test
avail
rhinovirus
hmpv
coronavirus
serolog
valu
diagnosi
acut
infect
virus
sever
previous
discuss
multiplex
molecular
assay
detect
respiratori
virus
detect
mani
respiratori
virus
routin
diagnosi
hepat
virus
base
serolog
serum
plasma
use
assay
separ
blood
within
hour
collect
diagnosi
acut
hav
made
demonstr
igm
antihav
immun
hav
follow
natur
infect
immun
determin
measur
hepat
igg
total
igg
igm
antihav
current
role
revers
transcript
rt
pcr
measur
hav
rna
routin
diagnosi
acut
chronic
hbv
infect
hbsag
antihepat
b
core
antibodi
hbcab
usual
present
igm
antihbc
gener
present
acut
hbv
infect
occasion
flare
inflamm
chronic
carrier
thu
igm
antihbc
alway
distinguish
acut
chronic
infect
definit
person
persist
posit
hbsag
month
use
confirm
cell
cultur
cpe
immunohistochem
stain
tissu
immunosuppress
patient
infect
associ
signific
morbid
mortal
proof
causat
difficult
specif
antibodi
absent
demonstr
viral
dna
pbmc
repres
latent
infect
although
pcr
detect
dna
serumplasma
low
sensit
may
better
marker
activ
infect
pcr
neg
serum
plasma
healthi
adult
posit
patient
exanthem
subitum
bone
marrow
transplant
recipi
hivinfect
patient
serolog
test
avail
wide
degre
crossreact
antibodi
occur
due
crossreact
epitop
virus
respons
distinguish
antibodi
avid
test
signific
rise
antibodi
stabl
absent
antibodi
may
indic
activ
infect
isol
saliva
healthi
adult
well
ill
individu
question
valu
test
isol
rare
pbmc
healthi
asymptomat
individu
compar
activ
infect
suggest
pbmc
cultur
may
diagnost
valu
specif
primer
pcr
amplif
develop
amplifi
dna
human
herpesvirus
includ
multiplex
assay
test
avail
research
set
pcr
use
detect
dna
pbmc
tissu
use
plasmaserum
pcr
valu
identifi
activ
infect
serolog
assay
detect
iggbut
igmanti
use
seropreval
studi
role
serolog
test
diagnos
manag
infect
establish
respiratori
syncyti
viru
np
wash
aspir
superior
swab
sampl
detect
rsv
infect
bronchoalveolar
lavag
bal
endotrach
tube
ett
aspir
also
accept
specimen
cultur
fa
test
transport
wet
ice
refriger
soon
collect
possibl
substanti
loss
cell
cultur
infect
room
temperatur
sampl
antigen
detect
transport
room
temperatur
cultur
rsv
requir
mean
day
shell
vial
cultur
appear
slightli
greater
sensit
standard
cultur
cultur
advantag
detect
respiratori
virus
recov
specimen
submit
diagnosi
rsv
infect
use
mix
fresh
cell
proven
rapid
sensit
method
detect
rsv
sensit
antigen
detect
techniqu
eia
microtit
plate
kit
membran
filter
eia
dfa
rang
specif
membran
filter
eia
offer
advantag
provid
result
within
minut
assay
detect
multipl
respiratori
virus
simultan
gener
rapid
antigen
detect
test
rsv
rel
lower
sensit
adult
children
like
reflect
decreas
amount
durat
shed
rsv
respiratori
secret
adult
use
serolog
test
diagnosi
acut
rsv
infect
littl
clinic
valu
primari
rsv
infect
detect
igm
antibodi
appear
approxim
day
onset
symptom
persist
sever
week
antibodi
respons
may
poor
absent
young
infant
older
individu
repeat
infect
immunocompromis
patient
rsv
antibodi
detect
may
use
epidemiolog
purpos
evalu
respons
candid
rsv
vaccin
naat
improv
detect
rsv
respiratori
tract
specimen
use
distinguish
rsv
subgroup
b
commun
institut
outbreak
multiplex
pcr
assay
capabl
detect
sever
respiratori
virus
test
evalu
refer
avail
onlin
wwwexpertconsultcom
variabl
sensit
specif
igg
antihev
posit
patient
week
onset
diseas
becom
undetect
month
igg
antihev
typic
declin
infect
area
hev
endem
rtpcr
may
prove
use
confirmatori
test
stool
sampl
place
clean
steril
contain
without
vtm
preserv
detect
enter
virus
collect
within
first
hour
ill
rectal
swab
may
contain
suffici
viru
em
detect
stool
specimen
stabl
week
although
freez
permit
prolong
storag
em
detect
reduc
repeat
freez
thaw
destroy
morpholog
viral
structur
none
enter
virus
cultiv
readili
convent
cell
cultur
system
detect
em
commerci
eia
latex
agglutin
membranebas
test
sensit
specif
avail
detect
rotavirus
norovirus
enter
adenovirus
astrovirus
pcrbase
assay
virus
becom
avail
mani
state
health
depart
pcrbase
assay
method
choic
diagnos
enter
virus
particularli
rotavirus
calicivirus
role
serolog
test
enter
virus
except
outbreak
investig
enterovirus
gener
stabl
surviv
environ
week
rapid
transport
clinic
specimen
laboratori
critic
enteroviru
viabil
decreas
slowli
day
week
room
temperatur
preserv
decad
appropri
specimen
includ
csf
serum
whole
blood
pericardi
fluid
tissu
biopsi
eg
myocardium
urin
stool
rectal
nasal
throat
swab
although
mani
enterovirus
grown
cell
cultur
serotyp
eg
coxsackieviru
group
fail
grow
standard
cell
cultur
isol
enteroviru
requir
day
viru
isol
frequent
stool
throat
swab
csf
serum
peripher
leukocyt
due
lack
common
antigen
among
enterovirus
immunoassay
direct
detect
avail
em
use
diagnosi
low
number
virus
clinic
sampl
rtpcr
use
test
csf
cardiac
tissu
pericardi
fluid
well
serum
significantli
improv
speed
detect
enterovirus
report
sensit
specif
comparison
cultur
sensit
detect
urin
sampl
poor
probabl
due
nonspecif
inhibitor
pcr
respiratori
specimen
crossamplif
rhinovirus
occur
clinic
detect
enterovirus
must
interpret
cautious
asymptomat
shed
wild
enteroviru
gastrointestin
tract
occur
week
month
addit
oral
polio
vaccin
viru
shed
stool
less
commonli
throat
young
vaccin
children
detect
viru
csf
genitourinari
tract
tissu
blood
proof
caus
role
measur
antibodi
titer
enterovirus
limit
diagnost
valu
separ
neutral
assay
must
perform
enteroviru
subtyp
laboratori
diagnosi
mmr
virus
made
viru
isol
detect
antigen
use
rtpcr
serolog
test
suitabl
sampl
isol
detect
viral
antigen
includ
whole
blood
particularli
pbmc
isol
measl
serum
throat
np
secret
urin
appropri
clinic
circumst
csf
brain
skin
biopsi
labil
virus
rapid
transport
laboratori
consid
chronic
infect
isol
antihbc
posit
occur
acut
infect
loss
detect
hbsag
emerg
detect
hbsab
core
window
late
chronic
infect
hbsag
level
fallen
detect
level
coinfect
hcv
hiv
suppress
hbsag
product
infect
mutant
hbv
falseposit
result
role
quantit
hbsag
assay
evalu
monitor
patient
chronic
hepat
b
infect
presenc
hbv
e
antigen
hbeag
absenc
antihb
marker
greater
infect
correl
increas
risk
progress
chronic
hepat
cirrhosi
hepatocellular
carcinoma
presenc
antihb
indic
like
recoveri
presenc
hbsab
level
iu
ml
consid
protect
acut
infect
hbsab
level
declin
iuml
year
substanti
number
vaccin
respond
individu
remain
protect
acut
infect
like
result
immun
memori
presenc
hbsab
alon
reflect
prior
immun
wherea
presenc
hbsab
togeth
hbcab
reflect
recoveri
previou
natur
infect
diagnosi
hcv
infect
secondand
thirdgener
eia
supplementari
recombin
immunoblot
assay
riba
use
recombin
structur
protein
avail
wide
seroconvers
occur
week
follow
acut
infect
sensit
except
immunosuppress
individu
specif
supplementari
riba
test
hcv
antibodi
antihcv
frequent
neg
onset
jaundic
presenc
hcv
antibodi
indic
current
infect
patient
assay
avail
current
detect
igm
antihcv
util
measur
hcv
antigen
serum
plasma
establish
molecular
assay
detect
quantif
hbv
hcv
viral
nucleic
acid
serum
use
determin
prognosi
select
candid
therapi
monitor
respons
therapi
lower
baselin
concentr
indic
better
prognosi
greater
likelihood
respons
treatment
patient
respond
antivir
treatment
demonstr
signific
drop
hbv
dna
hcv
rna
wherea
nonrespond
molecular
assay
also
avail
hbv
hcv
genotyp
antivir
resist
test
hcv
genotyp
use
epidemiolog
purpos
identifi
patient
like
respond
therapi
role
hbv
genotyp
less
well
establish
naat
detect
hcv
rna
serum
week
exposur
use
part
blood
organ
tissu
donor
screen
patient
indetermin
hcv
antibodi
result
riba
inconclus
clinic
situat
test
hepat
b
c
group
one
three
categori
acut
hepat
chronic
hepat
immun
statusprevi
exposur
suspect
acut
hepat
initi
test
igm
antihav
hbsag
antihcv
perform
neg
igm
antihbc
test
repeat
test
antihcv
recommend
week
situat
chronic
hepat
suspect
test
includ
hbsag
antihcv
also
may
test
antihbc
patient
screen
immun
andor
previou
infect
follow
test
total
igg
antihav
hbsab
hbcab
depend
whether
previou
infect
suspect
antihcv
marker
previou
infect
immun
serolog
test
avail
hepat
delta
agent
hdv
hepat
e
virus
hev
none
approv
food
drug
administr
fda
infect
hdv
occur
sole
conjunct
hbv
infect
test
antihdv
perform
patient
acut
chronic
infect
hbv
coinfect
hbv
hdv
antihdv
disappear
within
month
follow
recoveri
acut
infect
howev
hdv
superinfect
hbv
chronic
infect
patient
antihdv
gener
persist
indefinit
infect
becom
chronic
case
measur
hdv
rna
rtpcr
remain
research
test
igg
igm
antihev
measur
use
research
commerci
assay
due
use
differ
antigen
assay
show
signific
specimen
volum
requir
rang
ml
lower
limit
detect
dynam
rang
time
result
regardless
assay
format
plasma
must
separ
blood
cell
within
hour
collect
none
assay
approv
use
individu
infect
group
molecular
assay
avail
genotyp
detect
antiretrovir
resist
mutat
resist
test
recommend
prior
initi
therapi
treatment
failur
occur
phenotyp
assay
also
perform
purpos
mainstay
diagnosi
hiv
remain
hivspecif
serolog
use
screen
eia
less
commonli
particl
agglutin
assay
follow
confirmatori
test
use
wb
assay
serum
plasma
accept
specimen
test
system
dri
blood
spot
urin
saliva
also
avail
earli
eia
sensit
specif
exceed
diagnosi
hiv
infect
highrisk
group
howev
lowrisk
group
blood
donor
posit
result
fals
due
commonli
crossreact
antibodi
human
leukocyt
antigen
cell
lysat
use
antigen
prepar
falseneg
result
occur
due
antigen
heterogen
among
hiv
strain
particularli
group
recent
eia
kit
use
purifi
viral
antigen
cell
lysat
recombin
viral
protein
synthet
peptid
antigen
detect
group
assay
increas
sensit
specif
fewer
indetermin
result
current
avail
assay
detect
igg
igm
assay
fourthgener
screen
test
detect
antibodi
antigen
time
reduc
seroconvers
window
period
approxim
day
detun
also
known
sensitiveless
sensit
eia
capabl
measur
affin
hiv
antibodi
use
distinguish
recent
pastdist
hiv
infect
estim
incid
rate
wb
remain
princip
confirmatori
test
hiv
serolog
despit
fact
sensit
seroconvers
panel
inferior
thirdand
fourthgener
screen
test
separ
wb
test
must
use
confirm
wb
measur
antibodi
respons
protein
p
glycoprotein
gp
prone
give
high
rate
indetermin
result
due
detect
crossreact
antibodi
nonspecif
reaction
center
diseas
control
prevent
cdc
criterion
confirm
infect
presenc
antibodi
two
follow
antibodi
respons
protein
repres
neg
test
wherea
presenc
antibodi
requir
posit
interpret
indetermin
result
repeat
test
next
month
recommend
wb
result
remain
indetermin
person
consid
infect
lowrisk
popul
person
posit
screen
eia
test
result
indetermin
wb
rare
ever
infect
hiv
followup
serolog
test
ifa
test
detect
igg
igm
quit
sensit
specif
use
altern
wb
confirmatori
test
line
immunoassay
lia
use
confirm
includ
group
singl
test
rapid
pointofcar
test
screen
confirm
requir
minim
laboratori
equip
develop
yield
result
minut
compar
sensit
specif
thirdgener
eiabas
test
confirmatori
assay
differ
laboratori
diagnost
strategi
need
common
situat
hiv
infect
consid
adult
older
child
suspect
hiv
infect
adult
older
child
infect
hiv
week
month
expect
antibodi
posit
standard
approach
situat
perform
screen
eia
repeat
eia
duplic
test
posit
import
specimen
best
kept
prior
process
may
frozen
delay
hour
anticip
isol
viru
blood
greatest
day
rash
onset
declin
rapidli
within
day
thereaft
conjunctiv
np
sampl
isol
measl
viru
collect
day
day
onset
rash
throat
swab
rubella
viru
isol
usual
posit
collect
day
rash
onset
rapidli
becom
neg
within
day
mump
viru
isol
saliva
day
day
onset
parot
virus
cultiv
convent
cell
line
isol
requir
day
measl
mump
viru
week
rubella
viru
shell
vial
method
measl
viru
sensit
day
day
sensit
dfa
stain
np
swab
specimen
measl
viru
antigen
compar
cultur
throat
swab
urin
specimen
shell
vial
cultur
detect
mump
viru
compar
sensit
specif
tradit
cultur
molecular
diagnosi
use
virusspecif
rtpcr
use
detect
virus
use
genotyp
help
differenti
wildtyp
vaccineviru
strain
time
serum
specimen
collect
critic
mani
patient
igm
antibodi
time
rash
onset
suspect
measl
viru
infect
serum
collect
within
day
rash
onset
rubella
viru
infect
patient
igm
posit
day
rash
onset
although
tradit
mmr
serolog
test
hai
igg
antibodi
number
ifa
eia
igg
igm
kit
avail
commerci
declin
preval
viral
diseas
posit
predict
valu
igm
test
low
presenc
rheumatoid
factor
lead
falseposit
igm
result
reexposur
previous
vaccin
individu
individu
histori
natur
infect
result
secondari
igg
igm
respons
mump
igm
antibodi
persist
month
acut
ill
patient
im
parvoviru
infect
measl
viru
cmv
infect
crossreact
igm
antirubella
similarli
infect
parvoviru
rubella
viru
result
crossreact
igm
antimeasl
pregnant
women
igm
antirubella
confirm
second
igm
assay
detect
signific
rise
igg
andtibodi
avid
assay
igg
antibodi
measl
rubella
virus
avail
measur
virusspecif
igg
antibodi
use
determin
immun
statu
mump
viru
crossreact
paramyxovirus
occur
rubella
viru
igg
level
iuml
thought
repres
immun
case
major
diagnost
test
hiv
serolog
eia
ifa
wb
hiv
antibodi
eia
antigen
cultur
naat
detect
rna
plasma
provir
dna
whole
blood
pbmc
cultur
hiv
longer
use
routin
diagnosi
naat
use
diagnosi
infect
neonat
excel
sensit
specif
screen
test
rna
becom
part
routin
blood
organtissu
donor
screen
program
sinc
also
use
measur
specimen
type
includ
csf
cervic
secret
semin
plasmasemen
serum
use
naat
popul
known
hivseroposit
yield
falseposit
result
major
use
quantit
viral
load
assay
monitor
patient
respons
antiretrovir
therapi
intraassay
biolog
variabl
rna
level
chang
consid
clinic
relev
differ
molecular
assay
also
produc
signific
differ
viral
load
thu
baselin
valu
repeat
laboratori
test
chang
one
assay
anoth
assay
yield
lower
level
patient
serum
use
instead
plasma
blood
collect
acidcitratedextros
anticoagul
rather
edta
current
avail
commerci
assay
vari
refer
avail
onlin
wwwexpertconsultcom
cn
diseas
serum
csf
specimen
test
sensit
test
approach
day
ill
tradit
assay
cf
hai
test
larg
replac
fa
eia
serolog
crossreact
occur
among
antigen
relat
virus
eg
sle
west
nile
viru
japanes
enceph
dengu
powassan
flavivirus
neutral
test
remain
specif
test
serolog
diagnosi
arboviru
infect
neutral
antibodi
also
felt
best
indic
protect
immun
parvoviru
cultiv
routin
cell
cultur
thu
serolog
rise
igg
titer
presenc
igm
antibodi
mainstay
diagnosi
igm
antibodi
detect
serum
approxim
day
infect
rash
joint
symptom
begin
persist
sever
month
sensit
igm
antiparvoviru
exce
first
month
onset
symptom
igg
antibodi
appear
within
sever
day
igm
gener
persist
year
current
igg
assay
sensit
igg
indic
past
infect
reexposur
parvoviru
lead
rise
igg
antibodi
level
igg
avid
assay
help
distinguish
primari
secondari
infect
immunocompromis
individu
may
produc
antibodi
diagnosi
made
naat
detect
viral
dna
serum
specimen
type
parvovirusassoci
aplast
crisi
chronic
infect
congenit
infect
diagnos
pcr
analysi
serum
pcr
also
use
detect
parvoviru
dna
bone
marrow
aspir
cord
blood
sampl
amniot
fluid
cell
biopsi
specimen
placenta
fetal
tissu
case
fetal
hydrop
howev
parvoviru
dna
may
detect
serum
month
acut
infect
year
tissu
thu
diagnosi
acut
chronic
parvoviru
infect
may
requir
serolog
quantit
pcr
recommend
specimen
lab
test
virus
list
tabl
major
virus
test
perform
highli
special
research
refer
laboratori
major
virus
infect
fetus
newborn
infant
includ
cmv
vzv
hsv
rubella
parvoviru
hbv
hcv
hev
enterovirus
hiv
neg
matern
neonat
serolog
virus
gener
exclud
fetal
infect
detect
viru
via
cultur
antigen
detect
naat
may
requir
correct
diagnosi
made
cord
blood
yield
falseposit
falseneg
result
reli
upon
diagnosi
confirmatori
wb
test
repeat
eia
posit
result
serolog
test
indetemin
addit
test
antigen
hiv
dna
rna
cultur
pbmc
perform
set
high
risk
clinic
featur
infect
antigen
test
specif
sensit
antigen
test
vari
accord
clinic
diseas
statu
asymptomat
infect
peopl
patient
aidsrel
complex
patient
aid
confirm
vertic
transmiss
hiv
use
eia
wb
confound
presenc
matern
antibodi
month
age
symptomat
infant
month
age
detect
antigen
hiv
genom
cultur
viru
pbmc
reliabl
definit
test
sensit
cultur
naat
antigen
iga
antihivtest
earli
diagnosi
hiv
infect
young
infant
shown
tabl
discuss
chapter
diagnosi
clinic
manifest
hiv
infect
although
cultur
consid
gold
standard
pediatr
hiv
infect
naat
viral
dna
rna
sensit
individu
known
hiv
exposur
antibodi
viru
usual
detect
within
week
infect
base
thirdgener
screen
assay
hiv
antibodi
detect
infect
individu
within
week
infect
remain
patient
within
month
virtual
infect
immunocompet
individu
seroposit
month
exposur
mononucleosislik
syndrom
develop
individu
week
infect
antigen
appear
transient
period
arbovirus
major
arboviru
infect
laboratori
test
gener
perform
arbovirus
caus
cn
diseas
brief
low
level
viremia
occur
clear
patient
seek
medic
attent
thu
blood
specimen
viru
isol
naat
rare
yield
posit
result
unless
collect
prior
neuroinvas
phase
ill
arbovirus
includ
dengu
yellow
fever
sandfli
fever
venezuelan
enceph
colorado
tick
fever
rel
high
level
viremia
occur
persist
day
week
make
viru
isol
naat
blood
specimen
possibl
refer
laboratori
viru
isol
neurotrop
virus
brain
tissu
csf
occasion
success
acut
phase
infect
naat
sensit
case
arboviru
infect
diagnosi
establish
igg
seroconvers
detect
specif
igm
antibodi
collect
pair
acut
collect
first
week
ill
convalesc
collect
week
later
sera
recommend
singl
sampl
may
suffici
diagnosi
specif
igm
test
avail
eg
eastern
equin
encephalomyel
western
equin
encephalomyel
california
la
cross
viru
st
loui
enceph
sle
west
nile
viru
dengu
viru
howev
case
eg
west
nile
viru
virusspecif
igm
detect
serum
year
follow
infect
naat
approv
use
specimen
collect
extragenit
site
naat
specimen
type
children
approv
firstvoid
urin
ml
collect
clean
steril
contain
men
women
selfcollect
vulvovagin
swab
specimen
accept
use
naat
urin
specimen
naat
stabl
hour
room
temperatur
may
refriger
day
store
lower
month
process
test
c
trachomati
group
four
broad
categori
serolog
cultur
direct
detect
molecular
diagnosi
serolog
test
c
trachomati
genit
tract
infect
use
diagnosi
individu
patient
antibodi
c
trachomati
persist
life
infant
detect
igm
antic
trachomati
use
microimmunofluoresc
mif
test
diagnost
test
choic
chlamydi
pneumonia
matern
igg
antibodi
persist
infant
month
mif
test
sensit
serolog
test
one
detect
speciesand
serovarspecif
respons
eia
detect
igm
antibodi
infant
variabl
perform
compar
mif
test
eia
detect
antibodi
genusspecif
antigen
lipopolysaccharid
lp
chlamydi
elementari
reticul
bodi
specif
c
trachomati
interpret
singl
igg
antibodi
test
result
difficult
peopl
antibodi
c
pneumonia
cf
test
use
wide
diagnosi
psittacosi
lymphogranuloma
venereum
valu
diagnos
genit
tract
neonat
chlamydi
infect
cell
cultur
specif
approach
howev
rel
insensit
compar
naat
requir
cell
cultur
facil
slow
turnaround
time
day
bar
evalu
use
test
method
cdc
continu
recommend
cultur
urethr
specimen
women
asymptomat
men
np
specimen
infant
rectal
specimen
patient
vagin
specimen
prepubert
girl
shell
vial
cultur
method
improv
sensit
shorten
detect
time
hour
c
trachomati
inclus
diagnosi
often
accomplish
direct
detect
antigen
eia
dfa
assay
nucleic
acid
hybrid
assay
cytolog
examin
presenc
intracellular
inclus
eia
use
monoclon
polyclon
antibodi
detect
chlamydi
lp
suit
process
larg
number
specimen
sensit
gener
less
cultur
naat
posit
eia
usual
requir
valid
second
noncultur
method
especi
lowpreval
popul
pointofcar
eia
provid
result
minut
perform
poor
evid
regard
impact
clinic
outcom
lack
dfa
assay
use
monoclon
antibodi
direct
major
outermembran
protein
momp
permit
direct
visual
cellular
materi
obtain
assess
qualiti
specimen
elementari
bodi
intracellular
inclus
detect
within
minut
howev
dfa
test
requir
skill
laboratori
microscopist
larg
number
specimen
process
expedi
dfa
use
conjunctiv
respiratori
specimen
infant
nucleic
acid
probe
similar
sensit
antigen
detect
method
rel
specif
howev
dna
probe
test
without
previou
amplif
requir
special
transport
media
thu
preclud
use
anoth
test
specimen
confirm
posit
result
dna
probe
test
sensit
male
genit
secret
inferior
method
cytolog
examin
direct
smear
presenc
intracellular
inclus
use
detect
chlamydi
conjunct
neonat
diagnos
conjunct
genit
infect
adolesc
congenit
cmv
infect
best
diagnos
isol
cmv
urin
neonat
within
first
week
life
beyond
week
age
isol
cmv
urin
distinguish
congenit
perinat
postnat
infect
igm
anticmv
newborn
posit
congenit
infect
neonat
test
yield
falseposit
result
congenit
vzv
infect
diagnos
serolog
perinat
postnat
infect
vzv
well
hsv
enterovirus
usual
diagnos
convent
antigen
detect
cultur
techniqu
although
naat
test
prefer
enterovirus
serolog
diagnosi
neonat
hsv
infect
inappropri
respons
may
detect
week
infect
demonstr
rubella
igm
neonat
featur
consist
congenit
rubella
confirm
diagnosi
viru
isol
requir
week
parvoviru
infect
pregnanc
diagnos
mother
serolog
detect
igm
rise
igg
antibodi
level
diagnost
wherea
stabl
igg
titer
reflect
past
infect
neonat
posit
parvoviru
antibodi
month
suggest
infect
parvoviru
infect
fetu
hydrop
confirm
use
naat
viral
dna
fetal
blood
amniot
fluid
cell
chlamydia
chlamydophila
chlamydia
trachomati
chlamydophila
pneumonia
c
psittaci
caus
diseas
human
psittacosi
rare
children
confirm
serolog
c
trachomati
intracellular
pathogen
optim
specimen
diagnosi
mucos
epitheli
cell
rather
purul
materi
prefer
specimen
type
vari
test
method
age
group
test
follow
specimen
accept
cultur
postpubert
women
swab
cytobrush
specimen
collect
cervic
os
prepubert
girl
vagin
swab
adult
male
urethr
swab
insert
cm
rotat
boy
swab
urethr
meatu
discharg
present
infant
suspect
chlamydi
conjunct
purul
discharg
remov
follow
swab
scrape
palpebr
conjunctiva
yield
cultur
relat
directli
qualiti
specimen
transport
storag
condit
test
urin
specimen
use
cultur
poor
sensit
cultur
dacron
cottonor
rayontip
swab
aluminum
plastic
shaft
recommend
swab
wooden
shaft
calcium
algin
tip
may
inhibit
growth
femal
pool
urethr
cervic
swab
specimen
increas
cultur
sensit
approxim
swab
place
immedi
chlamydi
transport
media
contain
sucros
phosphat
sucros
phosphat
glutam
supplement
bovin
serum
antimicrobi
agent
transport
laboratori
within
hour
cultur
transport
media
also
accept
use
naat
freez
result
loss
viabil
freez
avoid
collect
endocerv
urethr
swab
specimen
eia
dfa
hybrid
test
naat
gener
similar
cultur
follow
instruct
manufactur
eia
dfa
test
swab
specimen
requir
refriger
swab
specimen
naat
stabl
room
temperatur
day
urin
vagin
rectal
np
femal
urethr
specimen
test
use
eia
dfa
hybrid
test
due
poor
sensit
accept
specimen
naat
includ
endocerv
vagin
urethr
swab
well
urin
adolesc
adult
refer
avail
onlin
wwwexpertconsultcom
rapid
accur
diagnosi
pneumonia
infect
problemat
due
lack
wellstandard
test
cultur
wide
accept
method
test
respiratori
tract
secret
avail
limit
special
broth
agar
media
requir
yield
rel
low
optim
isol
specimen
bal
tracheobronchi
secret
sputum
np
aspiratesswab
tissu
blood
csf
joint
fluid
inocul
appropri
media
eg
bedsid
media
accept
isol
pcr
assay
specimen
refriger
process
within
hour
pneumonia
rel
slowgrow
cultur
maintain
week
report
neg
shed
pneumonia
persist
sever
week
onset
ill
particularli
children
confound
interpret
posit
cultur
result
direct
antigen
test
eia
dfa
immunoblot
respiratori
tract
secret
sputum
np
aspir
perform
well
research
set
sensit
avail
wide
crossreact
commens
mycoplasma
occur
persist
shed
detect
antigen
asymptomat
individu
confound
interpret
posit
result
present
test
use
routin
clinic
set
convent
realtim
pcr
test
detect
pneumonia
respiratori
secret
wide
evalu
pcr
test
consist
sensit
cultur
antigen
detect
despit
rel
high
sensit
studi
suggest
pcr
use
alon
make
diagnosi
acut
recent
infect
result
must
use
conjunct
result
serolog
perform
csf
pcr
use
diagnosi
pneumoniaeassoci
meningoenceph
cf
assay
use
chloroformmethanol
glycolipid
extract
organ
best
valid
test
often
use
refer
method
serolog
diagnosi
measur
igg
igm
iga
antim
pneumonia
perform
commerci
avail
eia
fa
latex
agglutin
kit
sensit
specif
cf
replac
cf
mani
diagnost
laboratori
use
limit
fact
mani
children
igmneg
time
present
time
seroconvers
week
children
adolesc
young
adult
singl
posit
igm
result
consid
diagnost
although
falseposit
test
result
occur
combin
serolog
result
togeth
cultur
andor
pcr
may
provid
reliabl
approach
diagnosi
cold
agglutinin
antibodi
titer
simpl
perform
wide
avail
infect
pneumonia
develop
cold
agglutinin
antibodi
test
lack
sensitivityspecif
use
serolog
diagnosi
pneumonia
infect
genit
mycoplasma
major
mean
laboratori
diagnosi
u
urealyticum
homini
infect
cultur
organ
use
special
broth
agar
media
organ
grow
rapidli
cultur
posit
within
day
pcr
includ
multiplex
assay
use
detect
u
urealyticum
homini
clinic
specimen
genitalium
grow
slowli
cultur
may
posit
day
pcrbase
assay
mainstay
diagnosi
none
avail
commerci
serolog
test
genit
mycoplasma
standard
none
avail
commerci
serolog
test
use
eia
wb
ifa
littl
util
except
epidemiolog
tool
three
fdaapprov
molecular
diagnost
test
avail
simultan
detect
c
trachomati
neisseria
gonorrhoea
base
pcr
tma
sda
excel
sensit
specif
perform
hour
howev
perform
equal
well
specimen
type
genet
variant
c
trachomati
identifi
sweden
undetect
pcr
although
remain
local
dissemin
area
could
render
current
pcr
test
useless
highlight
potenti
vulner
test
mutat
within
target
region
organ
cultur
previous
consid
gold
standard
specif
excel
sensit
optim
techniqu
use
howev
genit
specimen
sensit
approxim
compar
naat
becom
prefer
test
diagnosi
genit
tract
infect
cervic
swab
specimen
eia
dfa
less
sensit
hybrid
test
naat
wherea
naat
provid
best
specif
posit
predict
valu
rapid
eia
test
rel
poor
sensit
use
urethr
swab
male
cervic
swab
femal
accuraci
specimen
type
well
evalu
test
firstvoid
urin
men
women
naat
median
specif
excel
sensit
result
high
posit
predict
valu
infant
conjunct
pneumon
test
conjunctiv
np
specimen
cultur
dfa
eia
produc
accept
result
studi
children
year
age
sda
tma
sensit
urin
specimen
vagin
swab
studi
sensit
vagin
swab
cultur
c
trachomati
case
suspect
rape
sexual
abus
recent
studi
guidelin
support
use
fdaapprov
naat
cultur
avail
posit
result
confirm
use
differ
naat
chlamydophila
pneumonia
accur
laboratori
confirm
acut
infect
c
pneumonia
difficult
often
base
serolog
mif
test
appear
reliabl
serolog
test
follow
criteria
posit
test
use
rise
titer
igm
titer
igg
titer
igg
titer
consid
evid
previou
necessarili
recent
infect
howev
limit
mif
test
lack
standard
avail
highqual
reagent
inabl
distinguish
past
persist
infect
comparison
eia
use
speciesspecif
assay
mif
shown
good
sensit
specif
children
respiratori
tract
diseas
control
children
eia
detect
antibodi
lp
test
detect
antibodi
chlamydia
speci
due
poor
sensit
cf
test
use
diagnosi
isol
c
pneumonia
difficult
stabil
c
pneumonia
clinic
specimen
well
studi
although
one
studi
report
organ
remain
viabl
hour
throat
swab
sputum
np
bal
respiratori
tract
specimen
place
transport
media
use
variabl
success
detect
organ
respiratori
secret
prove
causal
asymptomat
infect
occur
children
persist
shed
occur
month
acut
diseas
adult
addit
problem
cultur
includ
small
number
organ
present
respiratori
secret
poor
recoveri
unless
special
transport
media
optim
transport
storag
condit
use
limit
avail
molecular
diagnosi
noncommerci
convent
realtim
pcr
test
evalu
sensit
appear
good
cultur
specif
difficult
determin
given
lack
gold
standard
comparison
